Views: 1,372 | Downloads:
17
| Responses: 0
| XML | Respond to this article | Alert & updates | Request permissions | Email to a friend |
Original ArticleOpen Access
Is Prostate-Specific Antigen Still the Best Tumor Marker for Prostate Cancer?
Leewansangtong S 
,
Soontrapa S ,
Tantiwong A
,
Soontrapa S ,
Tantiwong A PSA has been utilized for more than a decade. Since the overwhelming benefit of PSA, the
previous markers for prostate cancer have been abandoned. Even though PSA is no more an organ
specific agent, its function as an organ specific marker remains in all clinical situations. PSA is significantly
involved not only in screening for early detection but also in all clinical spectrums of
prostate cancer. Never before has the tumor marker played such a significant role in all purposes of
clinical utilization for prostate cancer as PSA has. The answer to the title of this article is
absolutely positive. Nevertheless, the following question of whether PSA has an impact in decreasing
the mortality rate of patients with prostate cancer is yet to be answered. In Siriraj Hospital,
though PSA has been available since 1991, the majority of patients registered with the advanced
stage of disease and their treatment outcomes are not always satisfactory. Since the prognoses
of the patients with an early stage of disease appear very good, to improve the mortality of Thai
patients with prostate cancer, screening using PSA for early detection should he introduced and
widely used.
Key word : Prostate-Specific Antigen, Prostate Neoplasm, Prostate
previous markers for prostate cancer have been abandoned. Even though PSA is no more an organ
specific agent, its function as an organ specific marker remains in all clinical situations. PSA is significantly
involved not only in screening for early detection but also in all clinical spectrums of
prostate cancer. Never before has the tumor marker played such a significant role in all purposes of
clinical utilization for prostate cancer as PSA has. The answer to the title of this article is
absolutely positive. Nevertheless, the following question of whether PSA has an impact in decreasing
the mortality rate of patients with prostate cancer is yet to be answered. In Siriraj Hospital,
though PSA has been available since 1991, the majority of patients registered with the advanced
stage of disease and their treatment outcomes are not always satisfactory. Since the prognoses
of the patients with an early stage of disease appear very good, to improve the mortality of Thai
patients with prostate cancer, screening using PSA for early detection should he introduced and
widely used.
Key word : Prostate-Specific Antigen, Prostate Neoplasm, Prostate
Download:
PDF